|Lupinís Global Formulations business constitutes close to 84% of Lupinís overall business mix, and in terms of geographies, USA is its largest market outside India. 67% of the overall business of the Company comes from International Markets, hence Lupin has successfully nudged closer to its vision to be a research led international pharmaceutical company.
The Companyís wide product basket comprising formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments have been trusted by its patients and doctors across geographies.
The Company has moved up the value chain since inception in terms of its products and geographies. Currently, it commands a formulation business of over Rs 13,502 mn spread across the globe. Lupin has created a strong foothold in the Advanced Markets of USA, Europe, Japan, Australia and Emerging markets of India and some of the other Rest of World countries.